Higher orders and stronger cash flow helped the medtech group return to profit, despite margin pressure from tariffs and mix shifts.
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.